Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P01130: Variant p.Cys143Arg

Low-density lipoprotein receptor
Gene: LDLR
Feedback?
Variant information Variant position: help 143 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Cysteine (C) to Arginine (R) at position 143 (C143R, p.Cys143Arg). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and polar (C) to large size and basic (R) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In FHCL1. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 143 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 860 The length of the canonical sequence.
Location on the sequence: help SRQFVCDSDRDCLDGSDEAS C PVLTCGPASFQCNSSTCIPQ The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         SRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQ

Mouse                         SPQFVCDGDRDCLDGSDEAHCQATTCGPAHFRCNSSICIPS

Rat                           SRQFVCDQDWDCLDGSDEAHCAATTCGPAHFRCNSSSCIPS

Bovine                        APKFVCDLDLDCLDGSDEASCPMPTCGPANFQCNSSMCIPQ
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 22 – 860 Low-density lipoprotein receptor
Topological domain 22 – 788 Extracellular
Domain 107 – 145 LDL-receptor class A 3
Glycosylation 156 – 156 N-linked (GlcNAc...) asparagine
Disulfide bond 128 – 143
Alternative sequence 35 – 155 Missing. In isoform 6.
Alternative sequence 105 – 272 Missing. In isoform 3.
Alternative sequence 106 – 232 Missing. In isoform 2.
Helix 143 – 147



Literature citations
Identification of recurrent and novel mutations in the LDL receptor gene in German patients with familial hypercholesterolemia.
Nauck M.S.; Koester W.; Doerfer K.; Eckes J.; Scharnagl H.; Gierens H.; Nissen H.; Nauck M.A.; Wieland H.; Maerz W.;
Hum. Mutat. 18:165-166(2001)
Cited for: INVOLVEMENT IN FHCL1; VARIANTS FHCL1 ARG-143; TYR-148; TRP-184; CYS-574; ASP-639 AND ASP-806; VARIANTS TRP-257 AND ILE-742;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.